89 related articles for article (PubMed ID: 35219024)
1. Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3.
Zhao K; Dai Q; Wu J; Wei Z; Duan Y; Chen B
Eur J Cancer; 2022 Apr; 165():58-70. PubMed ID: 35219024
[TBL] [Abstract][Full Text] [Related]
2. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
Kosnopfel C; Wendlinger S; Niessner H; Siewert J; Sinnberg T; Hofmann A; Wohlfarth J; Schrama D; Berthold M; Siedel C; Sauer B; Jayanthan A; Lenz G; Dunn SE; Schilling B; Schittek B
J Exp Clin Cancer Res; 2023 Jul; 42(1):175. PubMed ID: 37464364
[TBL] [Abstract][Full Text] [Related]
4. Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers.
Shan KS; Rehman TU; Ivanov S; Domingo G; Raez LE
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203795
[TBL] [Abstract][Full Text] [Related]
5. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.
Smith MP; Sanchez-Laorden B; O'Brien K; Brunton H; Ferguson J; Young H; Dhomen N; Flaherty KT; Frederick DT; Cooper ZA; Wargo JA; Marais R; Wellbrock C
Cancer Discov; 2014 Oct; 4(10):1214-1229. PubMed ID: 25256614
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Smith MP; Brunton H; Rowling EJ; Ferguson J; Arozarena I; Miskolczi Z; Lee JL; Girotti MR; Marais R; Levesque MP; Dummer R; Frederick DT; Flaherty KT; Cooper ZA; Wargo JA; Wellbrock C
Cancer Cell; 2016 Mar; 29(3):270-284. PubMed ID: 26977879
[TBL] [Abstract][Full Text] [Related]
7. Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma.
Zecena H; Tveit D; Wang Z; Farhat A; Panchal P; Liu J; Singh SJ; Sanghera A; Bainiwal A; Teo SY; Meyskens FL; Liu-Smith F; Filipp FV
BMC Syst Biol; 2018 Apr; 12(1):33. PubMed ID: 29615030
[TBL] [Abstract][Full Text] [Related]
8. Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.
Wolfe Z; Friedland JC; Ginn S; Blackham A; Demberger L; Horton M; McIntosh A; Sheikh H; Box J; Knoerzer D; Federowicz B; Stuhlmiller TJ; Shapiro M; Nair S
Melanoma Res; 2022 Aug; 32(4):295-298. PubMed ID: 35551160
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma.
Kim S; Carvajal R; Kim M; Yang HW
Cell Rep; 2023 Jun; 42(6):112570. PubMed ID: 37252843
[TBL] [Abstract][Full Text] [Related]
10. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
Dankner M; Wang Y; Fazelzad R; Johnson B; Nebhan CA; Dagogo-Jack I; Myall NJ; Richtig G; Bracht JWP; Gerlinger M; Shinozaki E; Yoshino T; Kotani D; Fangusaro JR; Gautschi O; Mazieres J; Sosman JA; Kopetz S; Subbiah V; Davies MA; Groover AL; Sullivan RJ; Flaherty KT; Johnson DB; Benedetti A; Cescon DW; Spreafico A; Zogopoulos G; Rose AAN
JCO Precis Oncol; 2022 Aug; 6():e2200107. PubMed ID: 35977349
[TBL] [Abstract][Full Text] [Related]
11. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.
Young HL; Rowling EJ; Bugatti M; Giurisato E; Luheshi N; Arozarena I; Acosta JC; Kamarashev J; Frederick DT; Cooper ZA; Reuben A; Gil J; Flaherty KT; Wargo JA; Vermi W; Smith MP; Wellbrock C; Hurlstone A
J Exp Med; 2017 Jun; 214(6):1691-1710. PubMed ID: 28450382
[TBL] [Abstract][Full Text] [Related]
12. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies.
Hicks HM; Nassar VL; Lund J; Rose MM; Schweppe RE
Cancer Biol Ther; 2024 Dec; 25(1):2332000. PubMed ID: 38521968
[TBL] [Abstract][Full Text] [Related]
13. Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?
McKenna S; García-Gutiérrez L
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066022
[TBL] [Abstract][Full Text] [Related]
14. Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma.
Kozyra P; Pitucha M
Curr Med Chem; 2024; 31(15):2003-2020. PubMed ID: 37855341
[TBL] [Abstract][Full Text] [Related]
15. Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma.
Romano G; Paradiso F; Li P; Shukla P; Barger LN; El Naggar O; Miller JP; Liang RJ; Helms TL; Lazar AJ; Wargo JA; Taraballi F; Costello JC; Kwong LN
Cancer Immunol Res; 2023 May; 11(5):558-569. PubMed ID: 36820825
[TBL] [Abstract][Full Text] [Related]
16. Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.
Song K; Minami JK; Huang A; Dehkordi SR; Lomeli SH; Luebeck J; Goodman MH; Moriceau G; Krijgsman O; Dharanipragada P; Ridgley T; Crosson WP; Salazar J; Pazol E; Karin G; Jayaraman R; Balanis NG; Alhani S; Sheu K; Ten Hoeve J; Palermo A; Motika SE; Senaratne TN; Paraiso KH; Hergenrother PJ; Rao PN; Multani AS; Peeper DS; Bafna V; Lo RS; Graeber TG
Cancer Discov; 2022 Apr; 12(4):1046-1069. PubMed ID: 34930786
[TBL] [Abstract][Full Text] [Related]
17. STAG2 inactivation reprograms glutamine metabolism of BRAF-mutant thyroid cancer cells.
Li X; Liu Y; Liu J; Qiang W; Ma J; Xie J; Chen P; Wang Y; Hou P; Ji M
Cell Death Dis; 2023 Jul; 14(7):454. PubMed ID: 37479689
[TBL] [Abstract][Full Text] [Related]
18. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
Wang W; Edington HD; Jukic DM; Rao UN; Land SR; Kirkwood JM
Cancer Immunol Immunother; 2008 Sep; 57(9):1315-21. PubMed ID: 18386001
[TBL] [Abstract][Full Text] [Related]
19. Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles.
Hoffman TE; Nangia V; Ill CR; Passanisi VJ; Armstrong C; Yang C; Spencer SL
Sci Signal; 2023 Aug; 16(796):eade8744. PubMed ID: 37527351
[TBL] [Abstract][Full Text] [Related]
20. Cold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro.
Yan C; Zhao L; Zhang X; Chu Z; Zhou T; Zhang Y; Geng S; Guo K
J Biophotonics; 2024 Mar; 17(3):e202300356. PubMed ID: 38041219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
